BRIEF published on 04/15/2025 at 10:05, 10 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 10 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 10 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 1 month ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 1 month ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 1 month ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 5 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 5 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 02/14/2026 at 01:00, 1 day 18 hours ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 1 day 21 hours ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 2 days 1 hour ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 2 days 5 hours ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/15/2026 at 16:35, 3 hours 1 minute ago Arab Palestinian Investment Company (APIC) achieves USD 8.13 million in net income attributable to shareholders and reports record sales of USD 1.31 billion in 2025
Published on 02/15/2026 at 11:43, 7 hours 54 minutes ago EQS-Adhoc: The Management Board of Hapag-Lloyd Aktiengesellschaft confirms negotiations regarding an acquisition of Zim Integrated Shipping Services Ltd.
Published on 02/15/2026 at 11:05, 8 hours 31 minutes ago WePlay Debuts in German Market with "The Little Prince" Special Valentine's Day Collaboration
Published on 02/15/2026 at 09:35, 10 hours 1 minute ago Canary Islands at the Berlinale European Film Market with more than 40 professionals from the islands
Published on 02/14/2026 at 16:30, 1 day 3 hours ago Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/13/2026 at 18:05, 2 days 1 hour ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 2 days 1 hour ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 2 days 1 hour ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 2 days 1 hour ago Nombre total d'actions et droits de vote - janvier 2026
